LifeMine rounds out team with Stahl, Plamondon  

Small molecule drug discovery company  LifeMine Therapeutics Inc. hired Martin Stahl as CSO and Louis Plamondon as EVP and head of CMC. Stahl was global head of lead discovery at Roche (SIX:ROG; OTCQX:RHHBY), where he held several senior roles for 25 years. Plamondon was SVP and head of CMC at Constellation Pharmaceuticals Inc. Co-founded by Harvard University professor Gregory Verdine and serial entrepreneur Rick Klausner along with WuXi Healthcare Ventures entrepreneur-in-residence WeiQing Zhou, LifeMine raised $175 million in a series C round and unveiled a partnership with GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) in March.

Oncolytic virus company Theolytics Ltd. hired Andrew Oakley as CFO and Miriam Bazan-Peregrino as VP translational development. Oakley was CFO at Actelion Ltd., Vectura Group plc (LSE:VEC), Sosei Group Corp. (Tokyo:4565) and Autolus Therapeutics plc (NASDAQ:AUTL). Bazan-Peregrino was director of R&D at VCN Biosciences S.L...